Literature DB >> 15814101

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Kenneth J Valenzano1, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Susan L Gottshall, Lilly Mark, Michelle S Pearson, Wendy Miller, Shen Shan, Leyana Rabadi, Yakov Rotshteyn, Suzanne M Chaffer, Paul I Turchin, David A Elsemore, Mathew Toth, Lee Koetzner, Garth T Whiteside.   

Abstract

To date, two cannabinoid receptors have been identified, CB1 and CB2. Activation of these receptors with non-selective cannabinoid receptor agonists reduces pain sensitivity in animals and humans. However, activation of CB1 receptors is also associated with central side effects, including ataxia and catalepsy. More recently, a role for selective CB2 agonists in pain modification has been demonstrated. GW405833, a selective CB2 agonist, was recently reported to partially reverse the inflammation and hyperalgesia in a rat model of acute inflammation. In the current report, we extend the characterization and therapeutic potential of this compound. For the first time, we show that GW405833 selectively binds both rat and human CB2 receptors with high affinity, where it acts as a partial agonist (approximately 50% reduction of forskolin-mediated cAMP production compared to the full cannabinoid agonist, CP55,940). We also report for the first time that intraperitoneal administration of GW405833 (0.3-100 mg/kg) to rats shows linear, dose-dependent increases in plasma levels and substantial penetration into the central nervous system. In addition, GW405833 (up to 30 mg/kg) elicits potent and efficacious antihyperalgesic effects in rodent models of neuropathic, incisional and chronic inflammatory pain, the first description of this compound in these models. In contrast, analgesia, sedation and catalepsy were not observed in this dose range, but were apparent at 100 mg/kg. Additionally, GW405833 was not antihyperalgesic against chronic inflammatory pain in CB2 knockout mice. These data support the tenet that selective CB2 receptor agonists have the potential to treat pain without eliciting the centrally-mediated side effects associated with non-selective cannabinoid agonists, and highlight the utility of GW405833 for the investigation of CB2 physiology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814101     DOI: 10.1016/j.neuropharm.2004.12.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  83 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

Authors:  Peng Yang; Lirong Wang; Xiang-Qun Xie
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 4.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

5.  In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

Authors:  B B Yao; S Mukherjee; Y Fan; T R Garrison; A V Daza; G K Grayson; B A Hooker; M J Dart; J P Sullivan; M D Meyer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

6.  In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Authors:  B B Yao; G C Hsieh; J M Frost; Y Fan; T R Garrison; A V Daza; G K Grayson; C Z Zhu; M Pai; P Chandran; A K Salyers; E J Wensink; P Honore; J P Sullivan; M J Dart; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 7.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

8.  Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Qing-Rong Liu; Sanika S Chirwa; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.

Authors:  Jiaojiao Li; Jing Ji; Ruibo Xu; Zhengfu Li
Journal:  Medchemcomm       Date:  2019-09-17       Impact factor: 3.597

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.